Sangamo Therapeutics’ (SGMO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Sangamo Therapeutics (NASDAQ:SGMO) in a report published on Monday,Benzinga reports. The firm currently has a $10.00 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q4 2024 earnings at ($0.11) EPS, FY2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.08) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at ($0.02) EPS, FY2028 earnings at $0.19 EPS and FY2029 earnings at $0.42 EPS.

A number of other brokerages have also weighed in on SGMO. StockNews.com lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 24th. Barclays upped their target price on Sangamo Therapeutics from $3.00 to $9.00 and gave the stock an “overweight” rating in a report on Thursday, November 14th. Wells Fargo & Company lowered their target price on Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 31st. Jefferies Financial Group reduced their price target on Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, December 31st. Finally, Truist Financial lowered their price objective on Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, January 23rd. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat, Sangamo Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.17.

Sangamo Therapeutics Stock Performance

Shares of NASDAQ:SGMO opened at $1.13 on Monday. The company has a 50-day moving average price of $1.76 and a 200-day moving average price of $1.33. The company has a market cap of $235.77 million, a price-to-earnings ratio of -1.51 and a beta of 1.29. Sangamo Therapeutics has a 12 month low of $0.30 and a 12 month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. The business had revenue of $49.41 million during the quarter, compared to analyst estimates of $26.55 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. During the same quarter in the prior year, the company posted ($0.34) EPS. As a group, research analysts forecast that Sangamo Therapeutics will post -0.47 EPS for the current fiscal year.

Hedge Funds Weigh In On Sangamo Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of SGMO. Shelton Wealth Management LLC purchased a new stake in Sangamo Therapeutics during the 4th quarter valued at about $29,000. Sageworth Trust Co purchased a new stake in shares of Sangamo Therapeutics during the fourth quarter valued at approximately $61,000. Cubist Systematic Strategies LLC bought a new stake in shares of Sangamo Therapeutics during the second quarter valued at approximately $67,000. Meritage Portfolio Management raised its holdings in Sangamo Therapeutics by 8.6% in the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 6,740 shares during the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new stake in Sangamo Therapeutics during the 2nd quarter valued at $89,000. 56.93% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.